For patients with DLBCL treated with R-CHOP, our new prognostic index, which consists of Hb and clinical stages, may be helpful for selecting the treatment strategy, including investigational salvage therapy, although the effectiveness of our index should be validated in a larger cohort. The gene discussed is GSTM1; the disease is diffuse large B-cell lymphoma.